Abcellera Biologics Inc ABCL

$9.69 -0.78 (-7.45%)

Valuation

Market cap
3,419,691,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
4,247,300
Avg volume
4,262,794
Day's range
$9.58 – $10.26
Shares out
326,618,000
Stochastic %K
3%
Beta
1.59
Analysts
Strong Buy
Price target
$18.61

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Jwa68 Nov 21, 4:49 PM
$GANX A day will soon likely come here where the value of @microcapspevulator's past posts will become very self evident and seen as having been incredibly fortelling. Right aside of the comments of Ray Blanco who recommended $NVDA at $3, and $ABCL, Thomas Shrader (BTIG), Raghuram Selvaraju (H.C. Wainwright & Co.), Jason McCarthy (Maxim Group), Jay Olson (Oppenheimer & Co.), Boobalan Pachaiyappan (Roth) and Louise Chen at Scotia Bank who went as far as to call Gain a possible 🦄. Anyone taking the time to read and comprehend posts like this and others, can only better understand and appreciate the uniqueness of what rexacerat likely means to not just PD, but to the advancement of medical science and many other correlated diseases. There has never been a drug like it in history, a new science, both a blessing and a curse as a shareholder. The wave takes longer to build and crest, but when it does, it is a tsunami. Pharma is most interested in biomarkers, it appears Gain may have yet more coming. If pharma wants biomarkers, and Gain has them, then is it not logical to suspect pharma may too want Gain and the only available phase 2 ready safe and well tolerated PD asset that works on both GBA-1 and idiopathic, halts the progression of the disease, returns gate, balance and smell, is neuroprotective, and improves mitochondrial and lysomal health, central to aging. Again...asking for a friend. Ignore what I post and others here if you choose. We are all admittedly bias by our investments. That said, the growing list of respected, educated and accredited subject matter experts is growing at a nice clip. Do your own dd as always.
3 replies
Techdamentals Nov 21, 3:16 PM
$ABCL closed at $9.69 on Friday, November 20, down 7.4% on the day and 36% below its 52-week high. Before you make your next investment move, it helps to know what the business is actually worth. Techdamentals works that out from the company’s own numbers: 📏 A fair value range from the company’s own numbers, and where the price sits against it 📊 The fundamentals and 📈 the chart, each read for you 📄 What the earnings filing said, next to what analysts expected 🔔 Phone alerts when a saved stock crosses its range 🛍️ Black Friday, through Monday, Nov 30: Pro is $84 for your first year (then $100), or $5 a month for your first 2 months (then $10). Free 7-day trial, no card 👇 techdamentals.com/sale?ref=st&signup=1 Educational, not advice.
0 replies
Invest2Growcom Nov 21, 4:12 AM
$ABCL ABCL is down about 7.45 percent, near 9.69, even with analysts getting more bullish. Piper Sandler kept its Overweight rating and raised its target to 20 from 12, which is more than double today's price. It joins a string of upgrades since the Q3 report on November 9 and encouraging ABCL635 data: Stifel went to 14 from 9, StoneX to 15 from 11, and Lake Street initiated coverage with a Buy and a 19 dollar target on November 18. The consensus rating is Moderate Buy with an average target near 16.75. The stock itself has pulled back from the 11 area it traded at earlier this week. It now sits below its 50 day average of about 12.33, and its 52 week high is 15.02. So the analyst view and the chart are pointing in different directions right now. Follow me for more on the antibody names.
1 replies
estatebuyersmia Nov 21, 3:17 AM
$ABCL SAVE YOUR DOLLARS HERE.. THERE WILL BE TONS OF BIOTECHS TO TRADE.. WE ARE COMING UP ON TAX LOSS SEASON... BE PATIENT...
0 replies
estatebuyersmia Nov 21, 3:15 AM
$ABCL if $ABCL BREAKS 9.50, ITS GOING TO 8, BREAKS 8, IAM A BUYER.
0 replies
estatebuyersmia Nov 21, 3:13 AM
$ABCL The market has to correct here and biotechs will correct with it.
1 replies
Plan2TradeTrade2Plan Nov 21, 2:24 AM
$ABCL may take decades to recover from the 🍊man’s economic disaster, wars, tariffs, rfk jr and now, slowing ai support, which held him up.
0 replies
Plan2TradeTrade2Plan Nov 21, 2:18 AM
$ABCL Carl and Co were buying in the $10’s. I wonder if they have more powder to purchase, sub $10
0 replies